Adaptimmune Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c
August 8, 2016 7:03 AM EDTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
... More


